A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN (TC) VERSUS PACLITAXEL PLUS CISPLATIN (TP) IN STAGE IVB OR RECURRENT CERVICAL CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0505)

被引：0
|
作者：
Kitagawa, R. [1 ]
Katsumata, N.
Shibata, T.
Nakanishi, T. [2 ]
Nishimura, S. [3 ]
Nishio, S. [4 ]
Takano, M. [5 ]
Satoh, T. [6 ]
Yokota, H. [7 ]
Ochiai, K. [8 ]
Kigawa, J. [9 ]
Kobayashi, H. [10 ]
Kanato, K. [11 ]
Yoshikawa, H. [6 ]
Kamura, T. [4 ]
机构：
[1] NTT Med Ctr Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Gynecol Oncol, Aichi, Japan
[3] Osaka City Gen Hosp, Dept Gynecol Oncol, Osaka, Japan
[4] Kurume Univ, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan
[5] Natl Def Med Coll Hosp, Dept Obstet & Gynecol, Tokorozawa, Saitama, Japan
[6] Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki 305, Japan
[7] Saitama Canc Ctr, Dept Gynecol Oncol, Saitama, Japan
[8] Jikei Univ, Dept Obstet & Gynecol, Tokyo, Japan
[9] Tottori Univ, Dept Obstet & Gynecol, Yonago, Tottori, Japan
[10] Kyushu Univ, Dept Obstet & Gynecol, Fukuoka 812, Japan
[11] Natl Canc Ctr, Multiinst Clin Trial Support Ctr, JCOG Operat Off, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [21] Phase III randomized trial of doxorubicin plus cisplatin versus doxorubicin+24-h paclitaxel plus filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study
    Fleming, GF
    Filiaci, VL
    Bentley, RC
    Herzog, T
    Sorosky, J
    Vaccarello, L
    Gallion, H
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1173 - 1178
  • [22] Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213)
    Morizane, Chigusa
    Machida, Nozomu
    Honma, Yoshitaka
    Okusaka, Takuji
    Boku, Narikazu
    Kato, Ken
    Nomura, Shogo
    Hiraoka, Nobuyoshi
    Sekine, Shigeki
    Taniguchi, Hirokazu
    Okano, Naohiro
    Yamaguchi, Kensei
    Sato, Takuji
    Ikeda, Masafumi
    Mizuno, Nobumasa
    Ozaka, Masato
    Kataoka, Tomoko
    Kitagawa, Yuko
    Terashima, Masanori
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041)
    Nomura, H.
    Aoki, D.
    Takahashi, F.
    Katsumata, N.
    Watanabe, Y.
    Konishi, I.
    Jobo, T.
    Hatae, M.
    Hiura, M.
    Yaegashi, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    Ohe, Y.
    Ohashi, Y.
    Kubota, K.
    Tamura, T.
    Nakagawa, K.
    Negoro, S.
    Nishiwaki, Y.
    Saijo, N.
    Ariyoshi, Y.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 317 - 323
  • [25] A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043)
    Nomura, Hiroyuki
    Aoki, Daisuke
    Michimae, Hirofumi
    Mizuno, Mika
    Nakai, Hidekatsu
    Arai, Masahide
    Sasagawa, Motoi
    Ushijima, Kimio
    Sugiyama, Toru
    Saito, Motoaki
    Tokunaga, Hideki
    Omatsu, Kohei
    Nakanishi, Toru
    Watanabe, Yoh
    Saito, Toshiaki
    Yaegashi, Nobuo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.
    Ishikawa, Mitsuya
    Kitagawa, Ryo
    Shibata, Taro
    Tokunaga, Hideki
    Iwata, Takashi
    Nishio, Shin
    Takada, Toshio
    Mori, Masahiko
    Horie, Koji
    Kudaka, Wataru
    Kagabu, Masahiro
    Tanikawa, Michihiro
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group
    Gibson, MK
    Li, Y
    Murphy, B
    Hussain, MHA
    DeConti, RC
    Ensley, J
    Forastiere, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3562 - 3567
  • [28] Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
    Ohtsu, A
    Shimada, Y
    Shirao, K
    Boku, N
    Hyodo, I
    Saito, H
    Yamamichi, N
    Miyata, Y
    Ikeda, N
    Yamamoto, S
    Fukuda, H
    Yoshida, S
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 54 - 59
  • [29] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Hao, Chunfang
    He, Lihong
    Dong, Guolei
    Wang, Xiaorui
    Jia, Yongsheng
    Zhang, Li
    CANCER RESEARCH, 2015, 75
  • [30] Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study
    Fleming, GF
    Brurietto, VL
    Cella, D
    Look, KY
    Reid, GCH
    Munkarah, AR
    Kline, R
    Burger, RA
    Goodman, A
    Burks, RT
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2159 - 2166
12345